Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ravulizumab trial in adults with amyotrophic lateral sclerosis
MOH_2020-11-09_009024Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ravulizumab in amyotrophic lateral sclerosis (ALS), sponsored by Alexion Pharmaceuticals. Started May 2020; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2020-11-09_009024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-09_009024.